Commentary
Cardiovascular disease, rather than liver decompensation, remains the leading cause of morbidity and mortality in patients with NAFLD and NASH. A significant proportion of the cardiovascular risk in NASH is likely attributable to shared metabolic risk factors. Nevertheless, there is much interest in understanding the independent contribution of hepatic steatosis and associated inflammation and fibrosis to the cardiovascular risk in patients with NASH. It is imperative that clinicians understand the metabolic risk factors and subsequent manifestations of CVD in this population.
The purpose of this review by H. Shroff and LB VanWagner (Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA) is to provide an up-to-date summary focused on highlighting recent advances in the understanding of mechanisms, screening, prevention, and management of CVD in patients with NAFLD.
